Multimodal predictors of disability progression and processing speed decline in relapsing-remitting multiple sclerosis
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
The underlying mechanisms for neurodegeneration in multiple sclerosis are complex and incompletely understood. Multivariate and multimodal investigations integrating demographic, clinical, multi-omics, and neuroimaging data provide opportunities for nuanced analyses, aimed to define disease progression markers. We used data from a 12-year longitudinal multicenter cohort of 88 people with multiple sclerosis, to test the predictive value of multi-omics, T 1 -weighted MRI (lesion count and volume, lesion-filled brain-predicted age), clinical examinations, self-reports on quality of life, demographics, and general health-related variables for future functional and cognitive disability. Systematic increases in Expanded Disability Status Scale (EDSS) scores were used to stratify a progressive disability group (PDG) from relatively stabile disability. A processing speed decline group (PSDG) was defined by a ≥20% decrease from the maximum (cognitive) Paced Auditory Serial Addition Test score. We used a multiverse approach to identify which baseline variables were most predictive for PDG and PSDG memberships, considering multiple analysis paths.
Future disability (median area under the curve: mAUC=0.83±0.04, median Brier score: mBS=0.16±0.02) and the loss of processing speed (mAUC=0.89±0.05, mBS=0.10±0.03) could be successfully classified across models. Varibles significantly (median p-values<0.05) predicting stable disability included receiving disease modifying treatment at 12-year follow-up (median Odds Ratio: mOR PDG =7.44±4.07, p median =0.013, proportion of the OR’s directionality: PORSD=100%), lower baseline EDSS for each 1-unit (mOR PDG =0.25±0.11, p median =0.013, PORSD=100%), and counter-intuitively every year increase in baseline age (mOR PDG =1.12±0.04, p median =0.020, PORSD=100%), and lower vitamin A per 1 umol/L (mOR PDG =0.10±0.05, p median =0.016, PORSD=99.7%) and D levels per 1 nmol/L (mOR PDG =0.95±0.02, p median =0.025, PORSD=100%). Variables significantly predicting stable processing speed were receiving disease modifying treatment at 12-year follow-up (mOR PSDG =0.10±0.08, p median =0.013, PORSD=100%) and baseline PASAT score (mOR PSDG =0.86±0.03, p median =0.005, PORSD=99.73%). These findings were supported by an additional simulation study.
Concordant with the literature, disease modifying treatments influence disability progression, as well as a higher EDSS and PASAT scores at measurement start. Experimental and counterintuitive findings on vitamin A and D levels require further validation. The large variability across models suggests a strong influence of analytic flexibility, such as the selection of covariates.
